Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab
Why the study?
Are longitudinal changes in multiple biomarkers associated with cardiotoxicity in breast cancer patients treated with doxorubicin and trastuzumab?
Population
78 breast cancer patients undergoing doxorubicin and trastuzumab therapy
Design
Cohort
Follow-up
maximum 15 months
Authors
Discussion
Loading...
Member takes
Implication
Biomarker rises should not yet guide cardiotoxicity monitoring; leaves open utility pending prospective validation in breast cancer.
Structured PICO
Are longitudinal changes in multiple biomarkers associated with cardiotoxicity in breast cancer patients treated with doxorubicin and trastuzumab?
P
Population
78 breast cancer patients undergoing doxorubicin and trastuzumab therapy
I
Intervention
Measurement of 8 biomarkers (hs-cTnI, hsCRP, NT-proBNP, GDF-15, MPO, PlGF, sFlt-1, and gal-3) at baseline and every 3 months
O
Outcome
Cardiotoxicity defined by the Cardiac Review and Evaluation Criteriasafety
Longitudinal increases in MPO, PlGF, and GDF-15 are associated with the development of cardiotoxicity in breast cancer patients receiving doxorubicin and trastuzumab.
Cite This Study
Putt et al. (2015) studied this question.